Oral Serum-Derived Bovine Immunoglobulin/Protein Isolate Has Immunomodulatory Effects on the Colon of Mice that Spontaneously Develop Colitis

PLoS One. 2016 May 3;11(5):e0154823. doi: 10.1371/journal.pone.0154823. eCollection 2016.

Abstract

Dietary immunoglobulin concentrates prepared from animal plasma can modulate the immune response of gut-associated lymphoid tissue (GALT). Previous studies have revealed that supplementation with serum-derived bovine immunoglobulin/protein isolate (SBI) ameliorates colonic barrier alterations in the mdr1a-/- genetic mouse model of IBD. Here, we examine the effects of SBI on mucosal inflammation in mdr1a-/- mice that spontaneously develop colitis. Wild type (WT) mice and mice lacking the mdr1a gene (KO) were fed diets supplemented with either SBI (2% w/w) or milk proteins (Control diet), from day 21 (weaning) until day 56. Leucocytes in mesenteric lymph nodes (MLN) and in lamina propria were determined, as was mucosal cytokine production. Neutrophil recruitment and activation in MLN and lamina propria of KO mice were increased, but were significantly reduced in both by SBI supplementation (p < 0.05). The increased neutrophil recruitment and activation observed in KO mice correlated with increased colon oxidative stress (p < 0.05) and SBI supplementation reduced this variable (p < 0.05). The Tact/Treg lymphocyte ratios in MLN and lamina propria were also increased in KO animals, but SBI prevented these changes (both p < 0.05). In the colon of KO mice, there was an increased production of mucosal pro-inflammatory cytokines such as IL-2 (2-fold), IL-6 (26-fold) and IL-17 (19-fold), and of chemokines MIP-1β (4.5-fold) and MCP-1 (7.2-fold). These effects were significantly prevented by SBI (p < 0.05). SBI also significantly increased TGF-β secretion in the colon mucosa, suggesting a role of this anti-inflammatory cytokine in the modulation of GALT and the reduction of the severity of the inflammatory response during the onset of colitis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Animals
  • Body Weight / drug effects
  • Cattle
  • Colitis / immunology*
  • Colon / drug effects*
  • Colon / immunology*
  • Cytokines / metabolism
  • Immunity, Innate / drug effects
  • Immunoglobulins / administration & dosage
  • Immunoglobulins / metabolism
  • Immunoglobulins / pharmacology*
  • Immunologic Factors / administration & dosage
  • Immunologic Factors / metabolism
  • Immunologic Factors / pharmacology*
  • Inflammation Mediators / metabolism
  • Mice
  • Mucous Membrane / drug effects
  • Mucous Membrane / immunology
  • Serum / metabolism*
  • T-Lymphocytes / drug effects
  • T-Lymphocytes / immunology

Substances

  • Cytokines
  • Immunoglobulins
  • Immunologic Factors
  • Inflammation Mediators

Grants and funding

All experimental animals, reagents and analyses were funded by grant TRA2009-0317 from the Spanish Ministry of Science and Innovation; http://www.idi.mineco.gob.es/portal/site/MICINN/ (M. Moretó), and by grant RDITCRD07-1-0008 from CIDEM (Government of Catalonia, Spain); http://accio.gencat.cat/cat/ (JP). Entera Health Inc., APC Europe S.A. and APC Inc. also partially funded this study. The funders provided support in the form of salaries for authors JP, JMC, LR, JDC and EW, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the author contributions section.